Skip to main content
Tessa NewsLink
Paste a health news link, or browse
Latest checks

Source study found

Story checked

Could lowering high blood pressure be as simple as stimulating your ear? | ScienceDaily (opens in a new tab)

sciencedaily.com · 2026-10-24

Short answerEvidenceSource

Short answer

Mixed

Mixed.

One claim goes further than the study. One other point was not covered by the paper.

  • 4 supported
  • 1 overstated
  • 1 not covered

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

Mixed

One claim overstates the study. Four of six check out. One claim the study doesn't address.

  • 4 supported
  • 1 overstated
  • 1 not covered
Open claim evidence
3
Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

6 claims in this story

Showing all 6 claimsChoose a verdict to focus the list.

Claim 1 of 6OverstatedIn a clinical trial of 63 patients already taking medication, the treatment proved safe, easy to use at home, and well tolerated.View evidenceHide evidence

As stated63 patients

Why this verdict

The abstract supports a 63-participant trial in patients on antihypertensive medication and reports that tAN was safe and acceptable during home self-administration. However, the claim’s wording that the treatment “proved safe” and was “easy to use at home” is stronger than the abstract-level evidence: the profile notes no detailed adverse-event rates, severity data, or acceptability metrics, and the small sample limits precision for safety conclusions.

1

Study evidence

tAN was reported as safe and acceptable during the study period of home self‑administration.

“SCRATCH-HTN ... was a double-blind, sham-controlled, phase 2a trial”
2

Study evidence

No significant difference between tAN and sham in change in daytime ambulatory SBP at 3 months.Between-group difference 2.35 mm Hg (95% CI, -4.37 to 9.07); P=0.49

“The primary efficacy end point was change in daytime ambulatory SBP from baseline to 3 months.”
Claim 2 of 6Not coveredThe results come from the SCRATCH-HTN trial, published in Hypertension.View evidenceHide evidence

Why this verdict

The supplied profile supports that the evidence comes from the SCRATCH-HTN trial. However, the profile as supplied at abstract depth does not provide a journal citation field or otherwise verify that the paper was published in Hypertension, so that part of the claim is not verifiable from the provided evidence.

1

Study evidence

tAN was reported as safe and acceptable during the study period of home self‑administration.

“SCRATCH-HTN ... was a double-blind, sham-controlled, phase 2a trial”
2

Study evidence

No significant difference between tAN and sham in change in daytime ambulatory SBP at 3 months.Between-group difference 2.35 mm Hg (95% CI, -4.37 to 9.07); P=0.49

“The primary efficacy end point was change in daytime ambulatory SBP from baseline to 3 months.”
Claim 3 of 6SupportedA small device that gently stimulates nerves through the ear could offer a new way to tackle stubborn high blood pressure.View evidenceHide evidence

Why this verdict

The headline is speculative and hedged (“could offer”), and the abstract profile supports that tAN is a noninvasive device tested in uncontrolled hypertension, was safe/acceptable, and showed a possible greater response in participants with baseline SBP >160 mm Hg. The headline is somewhat more optimistic than the overall null efficacy result, but the story’s body explicitly notes that tAN did not significantly beat sham overall, so the speculative framing is not materially inconsistent with the abstract-level evidence.

1

Study evidence

tAN was reported as safe and acceptable during the study period of home self‑administration.

“SCRATCH-HTN ... was a double-blind, sham-controlled, phase 2a trial”
2

Study evidence

No significant difference between tAN and sham in change in daytime ambulatory SBP at 3 months.Between-group difference 2.35 mm Hg (95% CI, -4.37 to 9.07); P=0.49

“The primary efficacy end point was change in daytime ambulatory SBP from baseline to 3 months.”
Claim 4 of 6SupportedAlthough it did not significantly outperform a placebo overall, patients with more severe hypertension showed promising reductions in blood pressure.View evidenceHide evidence

Why this verdict

The abstract profile reports no significant overall difference between tAN and sham in daytime ambulatory SBP at 3 months, while a prespecified adjusted analysis found a significant treatment-by-baseline SBP interaction with greater response among participants with baseline SBP >160 mm Hg. The story frames the subgroup result as “promising,” which is appropriately hedged.

1

Study evidence

No significant difference between tAN and sham in change in daytime ambulatory SBP at 3 months.Between-group difference 2.35 mm Hg (95% CI, -4.37 to 9.07); P=0.49

“The primary efficacy end point was change in daytime ambulatory SBP from baseline to 3 months.”
2

Study evidence

A prespecified adjusted interaction analysis reported a significant treatment-by-baseline SBP interaction (P_interaction = 0.003); the abstract states participants with baseline SBP >160 mm Hg showed a greater response to tAN for change in daytime ambulatory SBP at 3 months.

“Pre-specified adjusted analysis identified a significant interaction between treatment and baseline SBP”
Claim 5 of 6SupportedResearchers observed no statistically significant difference in blood pressure change across the full study population between active stimulation and sham treatment.View evidenceHide evidence

Why this verdict

The abstract profile directly reports no significant between-group difference in daytime ambulatory SBP at 3 months between tAN and sham in the overall population, with a between-group difference of 2.35 mm Hg, 95% CI −4.37 to 9.07, P=0.49.

1

Study evidence

tAN was reported as safe and acceptable during the study period of home self‑administration.

“SCRATCH-HTN ... was a double-blind, sham-controlled, phase 2a trial”
2

Study evidence

No significant difference between tAN and sham in change in daytime ambulatory SBP at 3 months.Between-group difference 2.35 mm Hg (95% CI, -4.37 to 9.07); P=0.49

“The primary efficacy end point was change in daytime ambulatory SBP from baseline to 3 months.”
Claim 6 of 6SupportedA prespecified subgroup analysis found a greater reduction in blood pressure among participants with more severe hypertension who received active nerve stimulation versus sham.View evidenceHide evidence

Why this verdict

The profile states that a prespecified adjusted analysis found a significant treatment-by-baseline SBP interaction, and that participants with baseline SBP >160 mm Hg showed a greater response to tAN. The story’s wording is associational and hedged, though the abstract does not provide subgroup effect sizes, confidence intervals, or subgroup sample sizes.

1

Study evidence

No significant difference between tAN and sham in change in daytime ambulatory SBP at 3 months.Between-group difference 2.35 mm Hg (95% CI, -4.37 to 9.07); P=0.49

“The primary efficacy end point was change in daytime ambulatory SBP from baseline to 3 months.”
2

Study evidence

A prespecified adjusted interaction analysis reported a significant treatment-by-baseline SBP interaction (P_interaction = 0.003); the abstract states participants with baseline SBP >160 mm Hg showed a greater response to tAN for change in daytime ambulatory SBP at 3 months.

“Pre-specified adjusted analysis identified a significant interaction between treatment and baseline SBP”
Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

  • The abstract does not provide detailed adverse-event rates, severity information, or predefined acceptability metrics.

    This limitation is not acknowledged in the story. It is material because the story says the treatment “proved safe” and was easy to use, while the abstract-level profile only provides a high-level safety/acceptability conclusion without numerical safety or acceptability details.

    From Phase 2a randomized, double-blind, sham-controlled trial with home self-administered neuromodulation; Double-blind, sham

  • No significant differences were observed for other secondary endpoints, including BP, heart rate, and quality of life at 1 and 3 months.

    The story focuses on the primary efficacy result and the subgroup finding, but does not mention the abstract’s null findings for other secondary endpoints.

    From Double-blind randomized sham-controlled phase 2a trial

6 things the story did carry across
  • SCRATCH-HTN was a phase 2a double-blind, sham-controlled randomized trial of tAN versus sham in 63 adults with uncontrolled hypertension on at least one antihypertensive medication.
  • The primary safety/acceptability finding was that tAN was reported as safe and acceptable/well tolerated during home self-administration.
  • The trial did not demonstrate a significant overall blood-pressure-lowering effect versus sham for the primary efficacy outcome, daytime ambulatory SBP at 3 months.
  • A prespecified adjusted analysis found a significant treatment-by-baseline SBP interaction, with greater response among participants with baseline SBP >160 mm Hg.
  • The subgroup result lacks abstract-reported subgroup effect estimates, confidence intervals, and subgroup sample sizes, and requires confirmation in larger or targeted studies.
  • The small sample size and 2:1 randomization limit precision for both efficacy and safety estimates.
Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

4

Evidence read

study summary

Lead result

human in vivo

1Lead resulthuman in vivoEvaluate the safety and acceptability of a noninvasive transcutaneous autonomic neuromodulation (tAN) device in patients with uncontrolled hypertension in a double-blind, sham-controlled randomized trial.Phase 2a randomized, double-blind, sham-controlled trial with home self-administered neuromodulationExpand

In plain English

Phase 2a double-blind, sham-controlled randomized trial (SCRATCH-HTN) testing safety and acceptability of a self‑administered transcutaneous autonomic neuromodulation (tAN) device in 63 adults with uncontrolled hypertension; primary endpoints were safety and acceptability and primary efficacy endpoint was change in daytime ambulatory systolic BP (SBP) at 3 months. The device was reported as safe and acceptable; no significant between-group reduction in daytime ambulatory SBP at 3 months was observed overall, though a pre-specified adjusted analysis identified a significant interaction with baseline SBP (Pinteraction=0.003) with greater response among participants with baseline SBP >160 mm Hg.

Key findings

  • tAN was reported as safe and acceptable during the study period of home self‑administration.
  • No significant between-group reduction in daytime ambulatory systolic BP at 3 months was observed overall.Between-group difference 2.35 mm Hg (95% CI, −4.37 to 9.07); P=0.49
“SCRATCH-HTN ... was a double-blind, sham-controlled, phase 2a trial”
What this piece can’t prove
  • Small total sample size (63) and 2:1 randomization reduce precision for efficacy and safety estimates.
  • Abstract does not present detailed safety/adverse event data or predefined acceptability metrics.

2 further details could not be confirmed from the summary.

2human in vivoEvaluate the efficacy of tAN versus sham for lowering ambulatory blood pressure over 1 and 3 months (primary efficacy endpoint: change in daytime ambulatory SBP at 3 months), including prespecified adjusted/subgroup interaction with baseline SBP.Double-blind, sham-controlled randomized phase 2a trial (device vs sham)Expand

In plain English

Phase 2a double-blind, sham-controlled randomized trial (SCRATCH-HTN) comparing transcutaneous autonomic neuromodulation (tAN) versus sham in adults with uncontrolled hypertension; primary efficacy endpoint was change in daytime ambulatory systolic BP (SBP) from baseline to 3 months. In 63 randomized participants (2:1 tAN:sham, mean baseline daytime BP ≈150/95 mm Hg), there was no significant difference in daytime ambulatory SBP at 3 months (between-group difference 2.35 mm Hg, 95% CI -4.37 to 9.07; P=0.49) or at 1 month (-1.01 mm Hg, 95% CI -6.87 to 4.85; P=0.73). A prespecified adjusted analysis identified a significant interaction between treatment and baseline SBP (Pinteraction = 0.003), with greater response to tAN among participants with baseline SBP >160 mm Hg. tAN was reported as safe and acceptable; no other secondary endpoint differences were observed.

Key findings

  • No significant difference between tAN and sham in change in daytime ambulatory SBP at 3 months.Between-group difference 2.35 mm Hg (95% CI, -4.37 to 9.07); P=0.49
  • No significant difference between tAN and sham in daytime ambulatory SBP at 1 month.Between-group difference -1.01 mm Hg (95% CI, -6.87 to 4.85); P=0.73
“The primary efficacy end point was change in daytime ambulatory SBP from baseline to 3 months.”
What this piece can’t prove
  • Phase 2a trial with a modest sample size (N=63) which limits precision for detecting modest treatment effects.
  • Randomization 2:1 (tAN:sham) may affect power for between-group comparisons.

2 further details could not be confirmed from the summary.

3human in vivoEvaluate the efficacy of tAN versus sham for lowering ambulatory blood pressure over 1 and 3 months (primary efficacy endpoint: change in daytime ambulatory SBP at 3 months), including prespecified adjusted/subgroup interaction with baseline SBP.Prespecified adjusted interaction analysisExpand

In plain English

In the SCRATCH-HTN randomized, double-blind, sham-controlled trial (N=63, randomized 2:1 to tAN vs sham) a prespecified adjusted analysis tested treatment-by-baseline systolic BP (SBP) interaction for the primary efficacy outcome (change in daytime ambulatory SBP at 3 months). The adjusted interaction term was reported as statistically significant (P_interaction = 0.003), and the abstract states that participants with baseline SBP >160 mm Hg showed a greater response to transcutaneous autonomic neuromodulation (tAN). The abstract does not report subgroup effect estimates, confidence intervals, or model covariates in support of the interaction result.

Key findings

  • A prespecified adjusted interaction analysis reported a significant treatment-by-baseline SBP interaction (P_interaction = 0.003); the abstract states participants with baseline SBP >160 mm Hg showed a greater response to tAN for change in daytime ambulatory SBP at 3 months.
“Pre-specified adjusted analysis identified a significant interaction between treatment and baseline SBP”
What this piece can’t prove
  • Small overall trial sample and likely small subgroup sizes limit assessment of the interaction's reliability from abstract data alone.
  • Abstract does not report covariates included in adjusted models or any adjustments for multiple testing related to subgroup analyses.

1 further detail could not be confirmed from the summary.

4human in vivoAssess effects of tAN versus sham on secondary physiological and patient-reported outcomes (e.g., heart rate, quality of life) at 1 and 3 months.Double-blind randomized sham-controlled phase 2a trialExpand

In plain English

In the SCRATCH-HTN randomized, double-blind, sham-controlled phase 2a trial, pre-specified secondary endpoints of blood pressure, heart rate, and quality of life measured at 1 and 3 months showed no significant between-group differences between transcutaneous autonomic neuromodulation (tAN) and sham.

Key findings

  • Pre-specified secondary endpoints (blood pressure, heart rate, and quality of life) assessed at 1 and 3 months showed no significant differences between tAN and sham.
“Secondary end points included BP, heart rate, and quality of life at 1 and 3 months.”
What this piece can’t prove
  • Abstract omits effect estimates, confidence intervals, and specific p-values for the secondary outcomes, limiting quantitative appraisal.
  • Modest sample size and 2:1 randomization ratio in a phase 2a trial reduce precision and statistical power for secondary endpoint comparisons.

1 further detail could not be confirmed from the summary.

Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Papers considered

The selected paper, plus nearby candidates.

PubMed, Europe PMC, Crossref · 35 candidate papers

Candidate

A14390 Utility of Strain Rate Imaging in assessment of Sub-Clinical Cardiac status in Hypertensive patients

Journal of Hypertension · 2018 · Crossref

Source (opens in a new tab)

And 29 more candidates considered.